Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 14, 2026, at 11:15 a.m. PST / 2:15 p.m. EST, and will be accessible via a live and archived webcast on the company's investor relations website.

Rapport Therapeutics is at the forefront of developing small molecule precision medicines tailored for patients suffering from neurological and psychiatric disorders. The foundation of the company's innovative approach lies in the groundbreaking research of its founders, who have explored the roles of receptor associated proteins (RAPs) in the brain. This research has led to the establishment of Rapport's unique RAP technology platform, which is designed to generate novel precision small molecules that address several limitations associated with traditional neurology drug development.

The company’s pipeline features its lead investigational drug, RAP-219, targeted at achieving neuroanatomical specificity by selectively acting on a RAP found in specific brain regions. RAP-219 is currently being investigated for its potential efficacy in treating drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain.

Furthermore, Rapport Therapeutics is advancing additional preclinical programs and late-stage discovery projects that focus on chronic pain and hearing disorders. The company's commitment to developing targeted and effective therapies positions it as a promising player in the biotechnology sector, particularly in the field of neuroscience.

For further information, interested parties can reach out to Julie DiCarlo, the Head of Communications & IR, at Rapport Therapeutics.

Rapport Therapeutics, Inc. (Nasdaq: RAPP) presents a compelling investment opportunity as it prepares for its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company focuses on developing small molecule precision medicines for neurological and psychiatric disorders, leveraging its innovative receptor associated proteins (RAPs) technology platform.

Investors should particularly note the progress and potential of Rapport's lead investigational drug, RAP-219, a candidate treatment for drug-resistant focal onset seizures, bipolar mania, and diabetic peripheral neuropathic pain. The specificity of RAP-219 to target discreet brain regions could provide it with a substantial competitive edge over traditional therapies, potentially leading to better efficacy and fewer side effects. This is a critical factor as the market for treatments in these areas is considerable, driven by unmet medical needs.

Furthermore, the company is not just resting on its laurels with RAP-219; it has additional preclinical and discovery-stage programs targeting chronic pain and hearing disorders. This diversified pipeline reduces reliance on any single asset and spreads risk, which is attractive to investors seeking long-term growth potential in the biotech sector.

However, investors should be mindful of inherent risks in clinical-stage biotechnology investments, including regulatory hurdles and clinical trial outcomes. As Rapport approaches the conference, it will be essential to evaluate the reception of their presentation and any new data or insights that could affect investor sentiment.

In conclusion, while the opportunity is promising, potential investors should consider both the high reward and high risk associated with biotechnology stocks. Maintaining close attention to subsequent announcements and market reactions in the post-conference period will be crucial for making informed investment decisions.